Abstract
Cysteinyl leukotrienes (CysLTs) are potent inflammatory mediators that predominantly exert their effects by binding to cysteinyl leukotriene receptors of the G protein-coupled receptor family. CysLT receptor 2 (CysLT2R), expressed in endothelial cells of some vascular beds, has been implicated in a variety of cardiovascular functions. Endothelium-specific overexpression of human CysLT2R in transgenic mice (hEC-CysLT2R) greatly increases myocardial infarction damage. Investigation of this receptor, however, has been hindered by the lack of selective pharmacological antagonists. Here, we describe the characterization of 3-(((3-carboxycyclohexyl)amino)carbonyl)-4-(3-(4-(4-phenoxybutoxy)phenyl)-propoxy)benzoic acid (BayCysLT2) and explore the selective effects of this compound in attenuating myocardial ischemia/reperfusion damage and vascular leakage. Using a recently developed β-galactosidase–β-arrestin complementation assay for CysLT2R activity (Mol Pharmacol 79:270–278, 2011), we determined BayCysLT2 to be ∼20-fold more potent than the nonselective dual CysLT receptor 1 (CysLT1R)/CysLT2R antagonist 4-(((1R,2E,4E,6Z,9Z)-1-((1S)-4-carboxy-1-hydroxybutyl)-2,4,6,9-pentadecatetraen-1-yl)thio)benzoic acid (Bay-u9773) (IC50 274 nM versus 4.6 μM, respectively). Intracellular calcium mobilization in response to cysteinyl leukotriene administration showed that BayCysLT2 was >500-fold more selective for CysLT2R compared with CysLT1R. Intraperitoneal injection of BayCysLT2 in mice significantly attenuated leukotriene D4-induced Evans blue dye leakage in the murine ear vasculature. BayCysLT2 administration either before or after ischemia/reperfusion attenuated the aforementioned increased myocardial infarction damage in hEC-CysLT2R mice. Finally, decreased neutrophil infiltration and leukocyte adhesion molecule mRNA expression were observed in mice treated with antagonist compared with untreated controls. In conclusion, we present the characterization of a potent and selective antagonist for CysLT2R that is useful for discerning biological activities of this receptor.
Footnotes
This work was supported by the Canadian Institutes of Health Research [Grants MOP-79459, MOP-93689] (to C.D.F.); and a Natural Sciences and Engineering Research Council grant (to D.A.P.). C.D.F. holds a Tier I Canada Research Chair in Molecular, Cellular and Physiological Medicine and is recipient of a Career Investigator award from the Heart and Stroke Foundation of Ontario. D.A.P. holds a Tier II Canada Research Chair in Free Radical Chemistry.
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
doi:10.1124/jpet.111.186031.
↵ The online version of this article (available at http://jpet.aspetjournals.org) contains supplemental material.
-
ABBREVIATIONS:
- LT
- leukotriene
- CysLT
- cysteinyl LT
- CysLT1R
- CysLT receptor 1
- CysLT2R
- CysLT receptor 2
- hEC-CysLT2R
- human endothelial cell-specific CysLT2R overexpressor
- BayCysLT2
- 3-(((3-carboxycyclohexyl)amino)carbonyl)-4-(3-(4-(4-phenoxybutoxy)phenyl)-propoxy)benzoic acid
- Bay-u9773
- 4-(((1R,2E,4E,6Z,9Z)-1-((1S)-4-carboxy-1-hydroxybutyl)-2,4,6,9-pentadecatetraen-1-yl)thio)benzoic acid
- CPA
- cyclopiazonic acid
- DMSO
- dimethyl sulfoxide
- EtOAc
- ethyl acetate
- GAPDH
- glyceraldehyde 3-phosphate dehydrogenase
- HAMI3379
- 3-(((3-carboxycyclohexyl)amino)carbonyl)-4-(3-(4-(4-(cyclohexyloxy)butoxy)phenyl)propoxy)-benzoic acid
- HEK
- human embryonic kidney
- ICAM
- intracellular adhesion molecule
- I/R
- ischemia/reperfusion
- LAD
- left anterior descending coronary artery
- MK-571
- (E)-3-(((3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)((3-(dimethylamino)-3-oxopropyl) thio)methyl)thio)-propanoic acid
- MPO
- myeloperoxidase
- N-methyl-LTC4
- N-methyl-5S-hydroxy-6R-(S-glutathionyl)-7E,9E,11Z,14Z-eicosatetraenoic acid
- NMLTC4
- N-methyl LTC4
- PBS
- phosphate-buffered saline
- PCR
- polymerase chain reaction
- RLU
- relative light units
- rt
- room temperature
- TG
- transgenic
- THF
- tetrahydrofuran
- TLC
- thin-layer chromatography
- VCAM
- vascular cell adhesion molecule
- WT
- wild type.
- Received July 13, 2011.
- Accepted September 7, 2011.
- Copyright © 2011 by The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|